Quantcast
1 In 5 Men Reports Violence Toward Intimate Partners

1 In 5 Men Reports Violence Toward Intimate Partners

Beata Mostafavi, University of Michigan Physical symptoms like irritable bowel syndrome and insomnia also associated with higher risks of intimate partner violence One in five men in the U.S. reports violence towards their spouse or...

Latest irritable bowel syndrome Stories

2014-09-16 12:30:33

-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company's Investor Day in New York which highlighted its irritable bowel syndrome (IBS) program, including...

2014-09-10 12:29:04

-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board -- ROCKVILLE, Md., Sept. 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that its Investor Day to highlight...

2014-09-03 08:32:42

ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 16(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday,...

2014-09-02 08:31:53

- Potential Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) in Men and Women Granted Priority Review Status - DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D)....

2014-08-22 12:25:45

Dr. Glenn Madokoro educates patients on the signs of when it's probably a good time to make an appointment for a checkup at his Newport Beach, CA gastroenterology practice. NEWPORT BEACH, Calif., Aug. 22, 2014 /PRNewswire-iReach/ -- A lot of people hesitate to schedule an appointment with a doctor or specialist simply because they aren't sure when symptoms are serious enough to warrant a visit. Dr. Glenn D Madokoro, MD is educating patients on when it's a good idea to visit a...

2014-08-21 08:28:09

Sigma-Tau Pharmaceuticals Goal is to Broaden Consumer Awareness of VSL#3 and Meet Consumers at the Shelf; Pharmacy Cards Rolling Out At Stores Nationwide GAITHERSBURG, Md., Aug. 21, 2014 /PRNewswire/ -- Consumers have gotten used to seeing shelf cards in place of full product packages in certain categories of products, such as cold and flu, when either price or ingredients are deemed an issue for the store. Now, in an effort to offer consumers a different type of probiotic, one that...

2014-08-14 08:28:23

-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 -- ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three and six months ended June 30, 2014, and provided an operational...

2014-08-13 08:28:26

-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board -- ROCKVILLE, Md., Aug. 13, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in...

Disposable Biosensor Could Help Doctors Determine Which Patients Can Safely Eat Following Surgery
2014-08-12 03:39:29

University of California - Los Angeles Health Sciences Invention monitors an important new vital sign A disposal, plastic listening device that attaches to the abdomen may help doctors definitively determine which post-operative patients should be fed and which should not, an invention that may improve outcomes, decrease healthcare costs and shorten hospital stays, according to a UCLA study. Some patients who undergo surgery develop a condition called post-operative ileus (POI), a...

2014-08-12 08:31:24

Discounts are now available on IBS medications like Linzess or Amitiza allow patients to regain their quality of life MARGATE, N.J., Aug. 12, 2014 /PRNewswire-iReach/ -- Irritable Bowel Syndrome (IBS) may not sound serious, but for the roughly 15% of Americans who have to cope with it on a daily basis, it is anything but frivolous. The gastrointestinal tract makes up most of the human digestive system. When it isn't functioning properly, the result can be a host of uncomfortable...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'